Rigaku Announces Reorganization
News Oct 18, 2005
Rigaku has announced reorganization whereby the various operating companies and divisions of Rigaku, serving markets external to Japan and its core sales territories, began to operate as a single company.
As of September 1, 2005, Rigaku Americas Corporation (RAC) became the operating entity in charge of North America.
Over the last decade, Rigaku has acquired or founded a number of companies in order to develop a technology portfolio capable of sustained innovation for core markets.
During this period of high growth, the new additions retained their individual company identities.
With key capabilities now in place, top level integration will maximize the quality of solutions available to our customers while expediting the rollout of new advances.
Henceforth, all marketing and advertising material will brand the company solely as “Rigaku."
The new, combined organization (RAC) includes: Rigaku/MSC, Osmic, RoboDesign, Molecular Images, Electronic Imaging Technologies, Molecular Metrology, and the Vacuum Products division.
ActiveSight, Rigaku’s contract research organization (CRO), servicing the pharmaceutical and biotech markets, will continue to operate as a separate entity. The former Rigaku/MSC operation in the U.K will now be known as Rigaku Europe.
From a legal and formal standpoint, the transition will take place over the next few months, with the completion targeted for March 1, 2006.
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE